Q-omics provides the consensus-scored MS4A13 profile across patient tissues and cancer cell-line models. MS4A13 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MS4A13 is differentially expressed in 5, with the highest sampling consensus in LIHC. Additionally, MS4A13 RNA expression shows 7,049 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, LIHC, and TGCT as cancer lineages where MS4A13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MS4A13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MS4A13 survival associations across molecular data types. MS4A13 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MS4A13 RNA expression–survival associations across cancer types. High MS4A13 expression shows unfavorable associations in ACC, CESC, KIRP, KICH, KIRC and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MS4A13 RNA expression.
This table summarizes MS4A13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for MS4A13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MS4A13 shows higher tumor expression in LIHC, PRAD, KIRC, LUSC and LUAD. The LIHC box plot shows higher MS4A13 RNA expression in tumor versus normal tissue (log2 FC = +0.036, t-test p = .015).
This table shows molecular features associated with MS4A13 in patient tissues and cancer cell lines. In patient samples, MS4A13 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MS4A13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in CNS and LUNG_NSCLC_LUAD.
